Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling

T W. Grunt, G L. Mariani - Current cancer drug targets, 2013 - benthamdirect.com
Breast cancer is one of the most prevalent and devastating malignant diseases in women
worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is …

Targeting PI3K/AKT/mTOR signaling pathway in breast cancer

H Li, L Prever, E Hirsch, F Gulluni - Cancers, 2021 - mdpi.com
Simple Summary PI3K signaling pathway plays an essential role in many cellular processes
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

E Paplomata, R O'Regan - Therapeutic advances in medical …, 2014 - journals.sagepub.com
The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin
(mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and …

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients

SE Ghayad, PA Cohen - Recent patents on anti-cancer drug …, 2010 - ingentaconnect.com
Aberrant activation of the PI3K/Akt/mTOR pathway is found in many types of cancer and thus
plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The …

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions

JMS Bartlett - Clinical breast cancer, 2010 - Elsevier
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway regulates a broad spectrum of physiologic and pathologic processes. In …

The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts

M McKenna, S McGarrigle, GP Pidgeon - Biochimica et Biophysica Acta …, 2018 - Elsevier
Abstract The PI3K/Akt/mTOR pathway plays a role in various oncogenic processes in breast
cancer and key pathway aberrations have been identified which drive the different molecular …

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

S Chia, S Gandhi, AA Joy, S Edwards, M Gorr… - Current oncology, 2015 - mdpi.com
Abstract The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target of
rapamycin) signalling pathway is an established driver of oncogenic activity in human …

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

N Dey, P De, B Leyland-Jones - Pharmacology & therapeutics, 2017 - Elsevier
Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …

Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR

MA Ortega, O Fraile-Martínez, Á Asúnsolo… - Journal of …, 2020 - Wiley Online Library
Breast cancer is the cancer with the highest prevalence in women and is the number‐one
cause of cancer mortality worldwide. Cell transduction is a fundamental process in the …

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT

NA O'Brien, K McDonald, L Tong, E von Euw… - Clinical Cancer …, 2014 - AACR
Abstract Purpose: Altered PI3K/mTOR signaling is implicated in the pathogenesis of a
number of breast cancers, including those resistant to hormonal and HER2-targeted …